Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial
Abstract
7515
Background:
In DREAMM-8 (NCT04484623), BPd demonstrated a statistically significant, clinically meaningful benefit to progression-free survival (PFS) vs PVd in pts with RRMM who received ≥1 prior line of treatment including lenalidomide. MRD neg has been shown to be a predictor of PFS and overall survival (OS) in MM. We assessed efficacy outcomes by MRD status.
Methods:
Ptswere randomized (1:1) to BPd or PVd. The primary endpoint was independent review committee (IRC)–assessed PFS; OS, duration of response, and MRD status determined by next-generation sequencing with 10
−5
sensitivity threshold was assessed in pts with complete response or better (≥CR) every 6 mo until progressive disease. Post hoc subgroup analyses of PFS and OS were conducted based on IRC-assessed response (≥CR or ≥VGPR) and MRD-neg status using Kaplan-Meier method; CIs were estimated using Brookmeyer-Crowley method.
Results:
302 pts were randomized to BPd (n=155) or PVd (n=147). As previously reported (median follow-up, 21.8 mo), more pts with BPd had CR-based MRD neg vs PVd (37/155 [24%] vs 7/147 [5%]). A similar trend was seen in pts with ≥VGPR; 50/155 pts (32%) had VGPR-based MRD neg with BPd vs 8/147 (5%) with PVd. In the DREAMM-8 trial, MRD neg was associated with improved efficacy outcomes (Table). Pts with CR-based MRD neg had a lower risk of disease progression or death compared with pts without MRD neg (PFS HR, 0.14; 95% CI, 0.06-0.32; Table); median was NR overall and in each treatment arm…
Read the paper
Related studies
- Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- A meta‐analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale
- Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
- Exercise interventions in Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials
- Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
- Glucocorticoid Resistance: Is It a Requisite for Increased Cytokine Production in Depression? A Systematic Review and Meta-Analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.